Tagadatin

Information

Research

Order

The Innovation

Pharm

Home

Below is a partial list of references of the research on Tagatose

References for Tagatose

1: Kwak JH, Kim MS, Lee JH, Yang YJ, Lee KH, Kim OY, Lee JH. Beneficial effect of tagatose consumption on

postprandial hyperglycemia in Koreans: a double-blind crossover designed study. Food Funct. 2013

Aug;4(8):1223-8.

2: Donner TW, Magder LS, Zarbalian K. Dietary supplementation with d-tagatose in subjects with type 2 diabetes

leads to weight loss and raises high-density

lipoprotein cholesterol. Nutr Res. 2010 Dec;30(12):801-6.

3: Lo MC, Lansang MC. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based,

Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol. Am J Ther. 2013 Nov-Dec;20(6):638-53.

4: Luecke KJ, Bell LN. Thermal stability of tagatose in solution. J Food Sci. 2010 May;75(4):C346-51.

5: Espinosa I, Fogelfeld L. Tagatose: from a sweetener to a new diabetic medication? Expert Opin Investig Drugs.

2010 Feb;19(2):285-94

6: Police SB, Harris JC, Lodder RA, Cassis LA. Effect of diets containing sucrose vs. D-tagatose in

hypercholesterolemic mice. Obesity (Silver Spring). 2009

Feb;17(2):269-75. doi: 10.1038/oby.2008.508. Epub 2008 Nov 13.

7: Lu Y, Levin GV. Removal and prevention of dental plaque with d-tagatose. Int J Cosmet Sci. 2002 Aug;24(4):225-

34.

8: Lu Y, Levin GV, Donner TW. Tagatose, a new antidiabetic and obesity control drug. Diabetes Obes Metab. 2008

Feb;10(2):109-34. Epub 2007 Oct 15.

9: Moore MC. Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity. Curr Opin Investig

Drugs. 2006 Oct;7(10):924-35.

10: Food and Drug Administration, HHS. Food labeling: health claims; D-tagatose and dental caries. Final rule. Fed

Regist. 2003 Jul 3;68(128):39831-3.

11: Wong D. Sweetener determined safe in drugs, mouthwashes, and toothpastes. Dent Today. 2000

May;19(5):32, 34-5.

12: Levin GV. Tagatose, the new GRAS sweetener and health product. J Med Food. 2002 Spring;5(1):23-36.

13: Hugenholtz J, Smid EJ. Nutraceutical production with food-grade microorganisms. Curr Opin Biotechnol. 2002

Oct;13(5):497-507

14: Donner TW, Wilber JF, Ostrowski D. D-tagatose, a novel hexose: acute effects on carbohydrate tolerance in

subjects with and without type 2 diabetes. Diabetes Obes Metab. 1999 Sep;1(5):285-91.

15: Normén L, Laerke HN, Jensen BB, Langkilde AM, Andersson H. Small-bowel absorption of D-tagatose and

related effects on carbohydrate digestibility: an

ileostomy study. Am J Clin Nutr. 2001 Jan;73(1):105-10. Erratum in: Am J Clin Nutr 2001 Mar;73(3):665.

16: Bertelsen H, Jensen BB, Buemann B. D-tagatose--a novel low-calorie bulk sweetener with prebiotic properties.

World Rev Nutr Diet. 1999;85:98-109.

17: Buemann B, Toubro S, Astrup A. Human gastrointestinal tolerance to D-tagatose. Regul Toxicol Pharmacol.

1999 Apr;29(2 Pt 2):S71-7.

18: Buemann B, Toubro S, Raben A, Astrup A. Human tolerance to a single, high dose of D-tagatose. Regul Toxicol

Pharmacol. 1999 Apr;29(2 Pt 2):S66-70.

19: Saunders JP, Donner TW, Sadler JH, Levin GV, Makris NG. Effects of acute and repeated oral doses of D-

tagatose on plasma uric acid in normal and diabetic humans. Regul Toxicol Pharmacol. 1999 Apr;29(2 Pt 2):S57-65

20: Laerke HN, Jensen BB. D-tagatose has low small intestinal digestibility but high large intestinal fermentability

in pigs. J Nutr. 1999 May;129(5):1002-9.

21. Metts B, Thatcher S, Lewis E, Karounos M, Cassis L, et al. (2013) DDDAS Design of Drug Interventions for the

Treatment of Dyslipidemia in ApoE-/-

Mice. J Develop Drugs 2: 107

22. Bertelsen, H. et al. (2001): “Tagatose.” Alternative Sweeteners: Third Edition, Revised and Expanded. Ed. Lyn

O’Brien Nabors, 105-127.